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Abstract
Background: Broad-range fungal inter spacer region (ITS) polymerase chain reaction (PCR) has been evaluated for
the detection and identification of fungi in clinical specimens from severely immunocompromised patients, but not
in non-selected patients. Thus, the aim of this study was to compare the diagnostic performance of ITS PCR with that of
fungal culture and to investigate its clinical impact on the diagnosis of fungal infections in non-immunocompromised
patients. The corresponding patients’ data were retrieved by detailed medical chart reviews.
Results: Results from 251 specimens showed a high concordance of 89.6 % for ITS PCR and fungal culture. The analytical
sensitivity and specificity of ITS PCR considering culture as gold standard were 87.7 and 90.3 %, respectively, the positive
and negative predictive value (PPV and NPV) were 76 and 95.5 %, respectively. Assessing the clinical probability of a
fungal infection based on detailed chart reviews, PCR had a clinical sensitivity of 88.9 %, a specificity of 86.3 %, a PPV of
64.0 % and a NPV of 96.6 %. The overall performance of fungal broad-range PCR was similar to that of culture.
Conclusions: Our data show that, in non-selected and non-immunocompromised patients, the performance of ITS
PCR is similar to that of culture for detecting fungal infections, not the least because sensitivity of culture in patients
under antifungal treatment is surprisingly high. Compared to culture, PCR has the advantage of a rapid time-to-result
(approximately two working days), proper identification of rare pathogens, prompt initiation of a species-targeted
antifungal treatment, and prospects for automation.
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Background
The epidemiology of fungal infections has seen signifi-
cant changes over the last decades [1, 2]. In addition,
fungal infections are increasing due to more aggressive
chemotherapies, immunosuppressive therapeutics, and
biologicals interfering with the innate or adaptive immune
system [3]. Fungal infections are associated with high
morbidity and mortality [4, 5].
The clinic of fungal infections is often subtle and poten-
tially masked by bacterial infection(s) or comorbidities.
Clinicians consider and treat invasive fungal infections
(IFI) mainly in patients with prolonged and severe neutro-
penia [6], and in seriously ill patients with extensive can-
dida colonization [7]. In these selected patient groups,
decision to treat can be based on criteria established by
the European Organisation for Research and Treatment of
Cancer (EORTC) or using candida colonization indices
(CCI). However, in less selected patient groups, suspicion
of fungal infection mainly develops in patients with signs
of infection and an unfavorable clinical course, despite
treatment with antibiotics. No standardized evaluation cri-
teria or protocols exist for these situations and diagnosis
relies on a sophisticated work-up including imaging, biop-
sies, and serological or microbiological analyses. Surgical
site infections (SSI) are the third most frequently reported
nosocomial infection in hospitalized patients [8], and an
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increasing number of SSIs are attributable to fungi [9], in
particular Candida albicans [8, 9]. Compared to patients
with suspicion of IFI, an overtreatment is less acceptable
in patients with SSI [10, 11].
The gold standard for diagnosing invasive fungal infec-
tions is culture combined with histopathology [12, 13].
Biochemical assays such as 1, 3-beta-D-glucan or galac-
tomannan, which are based on the detection of released
fungal products in the blood stream are of value for
diagnosing IFIs [14], but have no value for local infec-
tions. [15]. DNA based assays excel by their speed and
the ability to identify a broad spectrum of fungi, including
rarely encountered species [16, 17]. The analytical and
clinical sensitivity of ITS PCRs has been previously inves-
tigated in selected patient cohorts with a high likelihood
of IFI e.g., hemato-oncologic patients [18–23]. Studies de-
termining the diagnostic value of ITS PCR in less selected
patient groups are limited. These patients do not fit into
the category of severely immunosuppressed patients, but
are potentially at risk to suffer from localized fungal infec-
tions such as patients with SSI. The goal of this study was
to evaluate the analytical and clinical sensitivity and speci-
ficity of ITS PCR in patients without overt immunosup-
pression in comparison to culture, and to explore its value
for diagnosis of fungal infections in daily practice.
Methods
Study design, clinical specimens and medical record review
We performed a retrospective data analysis of clinical
specimens from all patients hospitalized on surgical wards
for which fungal culture and ITS PCR was requested, in-
cluding patients surgically treated by ear/nose/throat spe-
cialists (ENTs), ophthalmologists and dermatologists at
the University Hospital of Zurich (USZ). The USZ is a ter-
tiary care 850-bed academic center in Switzerland. The
specimens were mainly from primarily sterile body sites
but also from the eye and from the ear-nose-throat area.
All specimens were analyzed by microscopy, conventional
culture methods and PCR based on the ITS region. The
clinical specimens were collected over a period of three
years. The sole exclusion criterion was insufficient chart
documentation for the clinical diagnosis of fungal in-
fection. The study was done according to good clinical
practice.
Diagnosis of fungal infection was done in the synopsis
of disease history, clinical picture and microbiological
work up (microscopy, culture, and PCR), and each pa-
tient was then categorized into definite fungal infection
or no infection. Data were obtained by medical chart review
and synopsis was done by a panel of 2 senior infectious
disease specialists (S.K.R. and R.F.S.) and 2 microbiologists
(A.Z. and G.V.B.) leading to an expert opinion. Data
was collected on underlying disease, clinical course of dis-
ease and interventions, clinical signs and symptoms of
inflammation, laboratory values (leucocytes, CRP, PCT),
additional diagnostics (radiology, pathology, and serology)
microbiological findings (microscopy, culture, serology),
and prior anti-infective treatment. The patients eventually
recruited had no overt immunosuppression; in particular
no patient was on glucocorticosteroids, drugs interfering
with T-cell function or on biologicals.
Microbiological analyses
Phenotypic methods
Clinical specimens were analyzed by microscopy and
culture methods for the presence of fungi as described
previously [24–26]. Phase contrast light microscopy of
clinical samples was performed after potassium hydroxide
treatment. Specimens were cultured on general mycology
media (Sabouraud dextrose agar containing gentamicin
and chloramphenicol, and brain heart infusion (BHI) agar;
Becton Dickinson AG, Allschwil, Switzerland) and on
fungal selective media (Chromagar, and Mycosel; Becton
Dickinson AG) for a maximum of 3 weeks at 25 °C and
were regularly examined for growth by eye. Subcultures for
identification were done as follows: (i) Aspergillus spp. on
malt yeast agar [13] at 25, 35, and 42 °C; (ii) mucorales on
potato carrot agar at 25, 37, 40, 45, 50, and 56 °C; (iii) all
other molds on Sabouraud dextrose agar containing genta-
micin and chloramphenicol at 25 and 35 °C and on Myco-
sel and potato carrot agar, both at 25 °C (temperatures as
routinely used in our clinical laboratory). Phenotypic iden-
tification was based on macro- and micro-morphological
criteria [26].
Genotypic methods
DNA extraction from clinical samples (stored at −20 °C)
was performed with an EZ1 DNA Tissue Kit (Qiagen,
Hombrechtikon, Switzerland) following the manufacturer’s
instructions. DNA extracts were eluted in 50 μl of PCR-
grade water (Limulus amebocyte lysate [LAL] water;
Lonza, Walkersville, MD) of which 5 μl was tested un-
diluted and in a 1:5 dilution to reduce possible inhibi-
tors of DNA polymerase activity. PCR was performed
using a Veriti PCR System (Life Technologies, Zug,
Switzerland) in a final volume of 23 μL containing
3 mmol/L MgCl2, 0.5 μmol/L of each primer ITS1 and
ITS4 [27], 2 μL of LightCycler FastStart DNA Master
SYBR Green I (LightCyler™ reagents; Roche, Rotkreuz,
Switzerland) and 5.0 μL of DNA extract. Cycling parame-
ters included an initial heating for 10 min at 37 °C, de-
naturation for 5 min at 95 °C, 40 cycles of 1 min at 94 °C,
1 min at 48 °C, and 1 min at 72 °C, and final elongation of
10 min at 72 °C. Subsequently, the reaction mixtures were
purified with the QIAquick PCR purification kit with a
final elution volume of 50 μL (Qiagen, Hombrechtikon,
Switzerland). Amplification products were visualized by
polyacrylamide gel electrophoresis combined with silver
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staining. Subsequently, a semi nested PCR was performed
using 2.0 μL of the purified reaction mixture and primers
ITS3 and ITS4, with the following PCR cycling parame-
ters; 10 min at 37 °C, denaturation for 5 min at 95 °C,
30 cycles of 1 min at 94 °C, 1 min at 50 °C, and 1 min at
72 °C, and final elongation of 10 min at 72 °C. After purifi-
cation with the QIAquick PCR purification kit, sequencing
was performed with primer ITS4 and ITS3 [27] using the
BigDye kit (Life Technologies, Zug, Switzerland) and an
automated DNA sequencer (ABI Prism 3130-Avant genetic
analyzer; Life Technologies, Zug, Switzerland).
Cultured isolates were subjected to DNA extraction using
the InstaGene matrix (Bio-Rad, Reinach BL, Switzerland)
followed by PCR amplification of the ITS regions and se-
quencing as described previously [25].
Sequences obtained (covering >90 % of at least one of
the ITS regions) were analyzed for homology using
GenBank (NCBI) and the SmartGene ITS database (ITS
validated database; SmartGene IDNS, Zug, Switzerland)
in parallel. Sequence assignment to species and genus
level was done according to guidelines published previously
(CLSI, 2008) [25].
The inhibition control consisted of amplification of a
422 bp fragment of the ipaH gene using E. coli K3
chromosomal DNA (~300 bacterial cells per reaction)
with primers Shig1 and Shig2 [28]. PCR was performed
with a Roche LightCycler 2.0 (Roche Diagnostics; Rotkreuz,
Switzerland) following manufacturers guidelines using
SYBR green for amplicon detection and 1.0 μL of DNA
extract. Reaction conditions were: pre-denaturation at
95 °C for 10 min, 50 cycles of denaturation at 95 °C for
1 s, annealing at 55 °C for 5 s and amplification for 35 s
at 72 °C. Candida albicans chromosomal DNA was used
as a positive PCR control. Buffers, PCR reagents, and elu-
tion column solutions were routinely tested for fungal
DNA contamination. If fungal identification in a clinical
sample was identical to the DNA contamination in one of
the controls, the sample was considered PCR negative. In
addition, samples were strictly considered negative if 1)
the specimen did not show a distinct PCR fragment on
polyacrylamide gel electrophoresis and 2) identification
pointed to a known environmental contaminant.
Statistics
We used the 2 × 2 contingency table to calculate sensi-
tivity, specificity, positive and negative predictive values
[29]. An overall Friedman (a non-parametric repeated
measure ANOVA test) was applied for calculating sig-
nificance between results of different methods [29].
Results
Clinical samples from surgical patients
In total, 251 clinical samples of 163 patients were in-
cluded in the study (Fig. 1): tissues (n = 92), swabs (from
wounds, n = 66; sternum, n = 5; eye, n = 27; ear, n = 4),
and liquid specimens (aspirates, n = 36; ascites, n = 18;
drain fluids, n = 3). Specimens were collected at different
surgical wards: visceral surgery (n = 80), cardiac surgery
(n = 51), thoracic surgery (n = 30), ophthalmology (n = 29),
traumatic surgery (n = 16), plastic surgery (n = 16), oto-
rhinolaryngology (n = 14), neurosurgery (n = 7), dentofacial
surgery (n = 4), dermatology (n = 3), and urology (n = 1).
Analytical sensitivity and specificity of ITS PCR compared
with conventional culture
Conventional fungal culture and histopathology are the
gold standard for the microbiological diagnosis of fungal
infections. Here we evaluated the concordance between
ITS PCR and culture. We assigned 49 specimens produ-
cing an ITS sequence as negative since these specimens
did not show a distinct PCR fragment on polyacrylamide
gel electrophoresis and identification pointed to known
environmental contaminants (Additional file 1: Table S1);
most of these species were Malassezia spp. (n = 16) and
Cladosporium sp. (n = 12).
We found a concordance of 89.6 % between PCR and
culture results (Tables 1 and 2). Doing both, i.e., PCR
and culture increased the diagnostic yield from 86 to
92 %. This increase was not significant (overall Friedman
test: x2 (2, N = 36) =2.00, P = 0.556). Discordant results
were observed in 26 samples with 8 (3.2 %) culture-positive
but PCR-negative samples and 18 (7.2 %) culture-negative
but PCR-positive samples. The analytical sensitivity of the
ITS PCR using culture as the gold standard was 87.7 %, the
analytical specificity was 90.3 % (Table 2), the positive pre-
dictive value was 76.0 %, and the negative predictive value
95.5 %. The majority of species identified in the specimens
by culture and/or PCR were Candida spp. (n = 54) and
Aspergillus spp. (n = 12) (Table 1). The other species
identified were Saccharomyces cerevisiae (n = 7), Cla-
dosporium sp. (n = 3), Rhodotorula minuta (n = 3), Paeci-
lomyces sp. (n = 2), Penicillium sp. (n = 3), Acremonium sp.
(n = 1), Colletotrichum sp. (n = 1), Mucor sp. (n = 1), Rhizo-
pus sp. (n = 2), Tulasnella sp. (n = 1), and Yarrowia lipoly-
tica (n = 1). Six specimens grew more than one fungal
species (Table 1). Microscopy-positive specimens gave
mostly (35/37) a culture-positive/PCR-positive result, while
this was much lower for microscopy-negative specimens:
22/46 microscopy-negative specimens were culture and
PCR-positive, 7/46 were culture-positive/PCR-negative, and
17/46 were culture-negative/PCR-positive (Table 1).
For discrepant results (n = 7), i.e., when species identifi-
cation by PCR was different from culture, we considered
the culture result as true positive and categorized the PCR
positive sample in the overall analysis as culture-positive/
PCR-negative. However, 4/7 samples, which were negative
by PCR, showed only one single fungal colony on the
agar plate or were positive only in enrichment cultures
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(3 Cladosporium sp., 1 Penicillium sp.) (Table 1). Since
microscopy was negative in these specimens, a contamin-
ation seemed likely. Considering these 4 samples as culture
negative, the analytical sensitivity of the PCR increased to
93.4 %, the specificity 90.5 %, the positive predictive value
76.0 % and the negative predictive value 97.7 %, res-
pectively (Additional file 1: Table S2). Notably, there
was only one culture-positive but PCR negative sample,
which showed mold hyphae by microscopy. The nega-
tive PCR result most likely reflects partial inhibition of
PCR (approximately 40 % as determined by RT PCR)
caused by traces of the black pigment produced by A. niger.
Clinical sensitivity and specificity of ITS PCR compared
with a composite diagnostic measure combining clinic
and microbiology data
Here, we examined the performance of broad-spectrum
PCR versus a composite diagnostic measure consisting
of clinical findings and microbiological results. 54/251
(21.5 %) patient samples from 35 patients categorized as
definite fungal infection were identified (Additional file 1:
Table S3). 7/54 specimens were culture negative and 47/54
were culture positive. The clinical sensitivity of fungal
culture was 87.0 %, the specificity 90.9 %, the positive
predictive value (PPV) 72.3 % and the negative predictive
value 96.2 % (Table 3). 4/7 culture-negative specimens
were PCR-positive with 3/7 A. fumigatus and 1/7 C. albi-
cans. (Additional file 1: Table S4a). These four culture-
negative/PCR-positive specimens were from three different
patients. In two of the three patients fungal infection was
known (aspergillosis, candidemia) and specimen collection
was performed under antifungal therapy. The third patient
(with post-operative intracranial abscess after meningioma
operation) was not under antifungal therapy at the time of
specimen collection; microscopy showed hyphae in one of
two samples and ITS PCR identified A. fumigatus in both
samples. 3/7 cases categorized as definite fungal infections
were culture- and PCR-negative. In these patients, micros-
copy was also negative. All of these patients were under an-
tifungal treatment (Additional file 1: Table S4b).
48/54 specimens from definite fungal infection cases
were PCR-positive and 6/54 specimens were PCR-negative.
In 2/6 PCR-negative cases, culture gave a positive result.
The clinical sensitivity of broad-range PCR was 88.9 %, the
specificity 86.3 %, the positive predictive value (PPV)
64.0 % and the negative predictive value (NPV) was 96.6 %
(Table 4).
36/54 specimens were obtained from patients, who re-
ceived antifungal treatment for 1 to 48 days (median
10.5 days) prior to sample collection. Notably, fungi were
recovered by culture in 31 of those 36 (86 %) specimens
(Table 5), 5/36 specimens from patients under antifungal
therapy were culture-negative. In 2 of the 5 cases, broad-
range PCR was positive. Overall, broad-range PCR was
positive in 31/36 specimens from patients under antifungal
therapy.
Microscopy
All specimens with both culture and PCR negative results
were microscopy negative. All specimens positive by mi-
croscopy were culture and/or PCR positive (Table 1). For
microscopy positive samples ITS PCR provides a rapid
Fig. 1 Enrollment of specimens
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mean of species identification (sensitivity of PCR for mi-
croscopy positive samples 97.3 %).
Discussion
The goal of this study was to evaluate the performance
of ITS PCR for diagnosis of fungal infections in patients
from surgical wards without overt immunosuppression.
We found a high concordance between PCR and culture
results regarding the analytical sensitivity and specificity
as well as the positive and negative predictive value. We
used a synopsis of clinical findings and laboratory results
to categorize patients into definite fungal infection or no
infection. On the basis of these composite diagnostic
Table 1 Fungal species identified by culture and/or broad-range PCR; specimens n = 83
Culture positive, PCR positive 57 Culture positive, PCR negative 8 Culture negative, PCR positive 18
Microscopy positive
(n = 37)
A. fumigatus 3 A. niger 1 A. fumigatus 1
C. albicans 13
C. albicansa and C. glabratab 2
C. albicansa, C. lusitaniaeb and S. cerevisiaeb 1
C. albicansa and Penicillium sp.b 1
C. glabrata 4
C. norvegensis 1
C. parapsilosis 2
C. tropicalis 1
Colletotrichum sp. 1
Paecilomyces sp. 1
Rhizopus sp. 1
S. cerevisiae 4
Total 35 1 1
Microscopy negative
(n = 46)
C. albicans 11 A. fumigatus 1 Acremonium sp. 1
C. albicansa and C. lusitaniaeb and S. cerevisiae 1 C. glabrata 2 A. fumigatus 2
C. albicansa and Rhizopus sp.b 1 Cladosporum sp.c 3 A. glaucus 2
C. glabrata 5 Penicillium sp.c 1 A. nidulans 1
C. kefyr 1 Aspergillus sp. 1
C. lusitaniae 1 C. albicans 2
Penicillium sp. 1 C. lipolytica 1
S. cerevisiae 1 Mucor sp. 1
Paecilomyces farinosus 1
Rhodotorula minuta 3
Tulasnella sp. 1
Yarrowia lipolytica 1
Total 22 7 17
adetected by PCR and culture
bdetected by culture from a specimen that grew more than one fungal species
cthese cultures were positive in culture by a single colony, or only in enrichment cultures
Table 2 Fungal ITS PCR compared to conventional culture
Culture
+ −
PCR + 57 (22.7 %) 18 (7.2 %)
− 8 (3.2 %) 168 (66.9 %)
A total of 251 clinical specimens were included in the study. For fungal
identification see Table 1. Abbreviations: −, negative; +, positive. Culture was
considered as the gold standard
Analytical sensitivity: 87.7 %, Positive predictive value (PPV): 76.0 %
Analytical specificity: 90.3 %, Negative predictive value (NPV): 95.5 %
Table 3 Fungal culture compared to composite diagnostic
measure for fungal infection including clinical findings and
microbiological results (number of samples n = 251)
Fungal infection
+ −
Culture + 47 18
− 7 179
Clinical sensitivity: 87.0 %, Positive predictive value (PPV): 72.3 %
Clinical specificity: 90.9 %, Negative predictive value (NPV): 96.2 %
Abbreviations: −, negative; +, positive
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measures the clinical sensitivity, specificity, PPV, and
NPV of ITS PCR and culture were in a similar range
(compare Tables 3 and 4). When considering patients
under antifungal treatment, we were surprised that PCR
did not add much to the sensitivity of culture for diag-
nosing fungal infections. Indeed, a similar number of
specimens were positive by culture and/or PCR. The
main advantage of PCR based detection is its diagnostic
speed, its prompt identification even of rare species, and
its ability to allow rapidly for a species-targeted treatment.
A major disadvantage of ITS PCR concerns the frequent
contamination of reagents and materials with traces of fun-
gal DNA [30]. As per the ubiquitous nature of fungi virtu-
ally every reagent may show low-level contaminations, e.g.,
primers, taq polymerase, etc., or contamination becomes
introduced during sampling. Strict precautions are neces-
sary, including careful quality control of the reagents, but
environmental contamination remains a problem. We used
two criteria to recognize environmental contamination and
to strictly categorize samples as negative: 1) the specimen
did not produce a distinct PCR fragment on polyacrylamide
gel electrophoresis, and 2) the species identified pointed to
a known environmental contaminant. Using these criteria,
we are confident that we have excluded PCR results which
were due to contaminations.
The analytical sensitivity of ITS PCR is in the range of
65 % to over 90 % [31, 32] in studies with highly selected
patient groups, namely severely immunocompromised pa-
tients, most of them with hemato-oncologic diseases and
diagnosed with either possible or probable IFI according
to the EORTC. However, other patients are also at risk of
fungal infections, especially after surgical interventions
[9]. Breach in the skin, a hyper-inflammatory state and an
excessive use of antibiotics [9] may render those patients
susceptible to fungal infections. Diagnosis of fungal infec-
tions is particularly delicate under these circumstances
and relies on suspicion and, the results of microbiological
investigations, namely microscopy and culture [12, 13].
Here we evaluated the value of ITS PCR for patients
mainly from surgical wards including patients hospital-
ized for diseases of the eye, ear/nose/throat or skin.
Samples studied included tissue specimens, swabs, and
liquid specimens. We found that the analytical sensitivity
of the ITS PCR considering culture as the gold standard
was 87.7 %, the analytical specificity 90.3 %, respectively.
The concordance between these two methods was as
high as 89.6 %. Thus we got overall similar results as in
previous studies with hemato-oncological or otherwise
severely immunocompromised patients [19]. We observed
discordant results in either direction, i.e., culture-positive/
PCR-negative (3.2 %) and culture-negative/PCR-positive
(7.2 %). Because of the high concordance between culture
and ITS PCR, performing both only minimally adds to the
likelihood to diagnose fungal infections. The diagnosis of
fungal infections has to integrate various elements, i.e.,
clinic data and information as well as results from micro-
biological investigations. The lack of a gold standard, inde-
pendent of culture and microscopy, hampers the evaluation
of new diagnostic methods. Our patient series included 7
culture-negative specimens from patients, whom we diag-
nosed to suffer from fungal infection based on history and
clinics, a number too low for assessing the diagnostic value
of PCR in culture-negative fungal infections.
Notably we observed sustained culture positivity despite
anti-fungal treatment. This may be explained by the in
general weak potency of antifungal drugs [33–35], empiri-
cal treatment not covering the fungal species eventually
identified (12/31), specimens obtained for microbiological
workup shortly after start of anti-fungal treatment (10/31
within 3 days), or poor drug penetration into surgical site
infection. This contrasts to bacterial infections where
broad-range bacterial PCR aids significantly in identifying
pathogens in patients treated with antibiotics [36].
Conclusions
In summary, in non-selected patients without overt im-
munosuppression, ITS PCR has a sensitivity and specifi-
city similar to that of conventional culture, but excels by
its speed (standardized time-to-result of 2 working days)
and identification of less frequently observed or emerging
fungal pathogens, allowing for rapid species-targeted
treatment. In addition, and in contrast to culture based
detection and identification of fungi, molecular diagnostic
procedures can readily be implemented in strategies for
full lab automation.
Table 4 Fungal ITS PCR compared to composite diagnostic
measure for fungal infection including clinical findings and
microbiological results (number of samples n = 251)
Fungal infection
+ −
PCR + 48 27
− 6 170
Clinical sensitivity: 88.9 %, Positive predictive value (PPV): 64.0 %
Clinical specificity: 86.3 %, Negative predictive value (NPV): 96.6 %
Abbreviations: −, negative; +, positive
Table 5 Fungal ITS PCR and conventional culture results for
specimens (n = 54) from patients with fungal infection - anti-fungal
treatment versus no treatment
Culture positive Culture negative
PCR positive 44 4
Under anti-fungal therapy 29 2
No anti-fungal therapy 15 2
PCR negative 3 3
Under anti-fungal therapy 2 3
No anti-fungal therapy 1 0
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Additional file
Additional file 1: MCRO-D-16-00030 R2 Supplemental data Rampini et al.
The supplemental data consist of four tables. Table S1. Compilation of false
positive PCR results categorized as contaminants; these specimens did not
produce a distinct PCR fragment on polyacrylamide gel electrophoresis and
identification pointed to known microbiological (environmental)
contaminants. Table S2. Fungal ITS PCR compared to conventional
cultures (n= 251). Four microscopy- and PCR-negative but culture positive
specimens as included in Table 2, were categorized as culture-negative since
cultures were only positive by a single fungal colony or only after enrichment
culture; thus, microbiological contamination was highly likely. Table S3.
Compilation of the patients with fungal infection (n = 54), including
microbiological data, clinical situation and antifungal therapy. Table S4.
Overview of culture negative fungal infections subdivided in (1) culture
negative, broad-range fungal PCR positive fungal infections and (2) culture
negative, broad-range fungal PCR negative fungal infections, including clinical
information and antifungal therapy. (DOCX 63 kb)
Abbreviations
BHI, brain heart infusion; CCI, candida colonization indices; CRP, C-reactive
protein; ENTs, ear/nose/throat specialists; EORTC, European Organisation for
Research and Treatment of Cancer; IFI, invasive fungal infections; ITS, inter
spacer region; NPV, negative predictive value; PCR, polymerase chain reaction;
PCT, procalcitonin; PPV, positive predictive value; SSI, surgical site infections
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